MPT0B002, identified by its CAS number 946077-08-3, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as molecular weight, structure, and solubility may vary, compounds in this category are often characterized by their unique functional groups and biological activity. MPT0B002 is typically studied for its interactions with biological targets, which may include enzymes or receptors involved in disease processes. Its efficacy and safety profile are evaluated through various in vitro and in vivo studies, contributing to its potential as a lead compound in drug development. Additionally, the compound's stability, reactivity, and pharmacokinetic properties are crucial for understanding its behavior in biological systems. As research progresses, detailed information regarding its mechanism of action and therapeutic potential continues to emerge, making it a subject of interest in pharmaceutical research.

MPT0B002 is a microtubule inhibitor. It acts by downregulating T315I mutant Bcr-Abl and inducing apoptosis of imatinib-resistant chronic myeloid leukemia cell.

MPT0B002

946077-08-3: MPT0B002, identified by its CAS number 946077-08-3, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as molecular weight, structure, and solubility may vary, compounds in this category are often characterized by their unique functional groups and biological activity. MPT0B002 is typically studied for its interactions with biological targets, which may include enzymes or receptors involved in disease processes. Its efficacy and safety profile are evaluated through various in vitro and in vivo studies, contributing to its potential as a lead compound in drug development. Additionally, the compound's stability, reactivity, and pharmacokinetic properties are crucial for understanding its behavior in biological systems. As research progresses, detailed information regarding its mechanism of action and therapeutic potential continues to emerge, making it a subject of interest in pharmaceutical research.

<p>MPT0B002 is a microtubule inhibitor that acts by downregulating T315I mutant Bcr-Abl and inducing apoptosis of imatinib-resistant chronic myeloid leukemia cells</p>

CAS 946077-08-3

MPT0B002

MPT0B002

Ref: TM-T24496